Polymorph myths

European Pharmaceutical Review

Volumn 19, Issue 3, 2014, Pages 24-29

  Threlfall, Terry ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CHALCONE; FLUFENAMIC ACID; GLYCINE; MANNITOL; PAROXETINE; PHENYLBUTAZONE; RANITIDINE; RIMONABANT; RITONAVIR; SULFATHIAZOLE;

CHEMICAL PHENOMENA; CRYSTAL STRUCTURE; CRYSTALLIZATION; DEFENSE MECHANISM; DRUG INDUSTRY; EMULSION; HUMIDITY; HYDROGEN BOND; INFRARED SPECTROSCOPY; MELTING POINT; NOMENCLATURE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATENT; POLYMORPHISM; PROCESS DEVELOPMENT; RAMAN SPECTROMETRY; REVIEW; SOLID STATE; SOLVATE; STOICHIOMETRY; THERAPEUTIC MISCONCEPTION; THERMODYNAMICS; TRANSITION TEMPERATURE; X RAY DIFFRACTION;

EID: 84907368874     PISSN: 13608606     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (61)

1. Bernstein J (2004) Paper presented at the Erice conference: erice2004.docking.org/vcourse/polymorph/19sat/1000...
2. Bauer J, Spanton S, Henry R, Quick J, Dziki W, Porter W, Morris J (2001) Ritonavir; An extraordinary example of conformational polymorphism. Pharm Res 18:859-866 (Pubitemid 32783524)
3. Bernstein J, Davey RJ, Henke J-O (2000) Concomitant polymorphs. Angew Chem Int Eng 38:3440-3461
4. Getsoian A, Lodaya RM, Blackburn AC (2008) One-solvent polymorph screen of carbamazepine. Int J Pharm 348: 3-9 (Pubitemid 350266231)
5. Thinunahari S, Chow PS, Tan RBH (2011) Quality by design (QbD) based crystallization process development for the polymorphs of tolbutamide. Cryst Growth Des 11:3027-3038
6. Price CP, Gresniak AL, Matzger AJ (2005) Crystalline polymorph selection and discovery with polymer heteronuclei J Amer Chem Soc 127:5512-5517 (Pubitemid 40569862)
7. Yu L (2007) Survival of the fittest polymorph: how fast nucleation can lose out to fast growth. CrystEngComm 9:741-751
8. Targett JJ (2005) The polymorphs and solvates of phenylbutazone and their phase transition behaviour. M Phil UCL London University:
9. Datta S, Grant DWJ (2005) Effect of supersaturation on the crystallization of phenylbutazone polymorphs Cryst Res Technol 40: 233-242
10. Han G, Chow PS, Tan RBH (2012) Direct comparison of α and γ growth rates in acidic and basic solution: New insights into glycine polymorphism. Cryst Growth Des 12:2213-2220
11. Greisser U, Burger A, Mereiter K (1997) The polymorphic drug substances of the European pharmacopoeia part 9. Properties and crystal structure of acetazolamide crystal forms J Pharm Sci 86: 352-358 (Pubitemid 27113771)
12. Beckmann W, Nikisch K, Budde U (1998) Development of a seeding technique for the crystallisation of the metastable A modification of Abecarnil. Org Process Res Dev 2:298-304
13. Bohlin M (1999) Effects of crystal habit and polymorphism on downstream processing: a case study. Paper presented at Aspects of Polymorphism and Crystallization Symposium Hinckley UK 23-25 June
14. Kuhnert-Brandstaetter M (1954) Thermomicroscopy in the Analysis of Pharmaceuticals. Pergamon Oxford
15. Kozisek Z (2013) Crystal nucleation kinetics in confined spaces. CrystEngComm 15:2269-2274
16. Dumas JP, Tounsi F, Babin L (1987) Phase transformations in emulsions part II: Polymorphism for organic substances. J Dispersion Sci Technol 8:29-54 (Pubitemid 17573707)
17. Kuhnert-Brandstaetter M, Riedmann (1987) Thermal analysis and infrared spectroscopic investigations of polymorphic organic compounds. Mikrochim Acta II 107-120
18. Lee AY, Lee IS, Dette SS, Boerner J, Myerson AS (2005) Crystallization on confined engineered surfaces: A method to control crystal size and generate different polymorphs. J Amer Chem Soc 127: 14982-14983 (Pubitemid 41547338)
19. Ha J-M, Wolf JH, Hillmeyer MA, Ward MD (2004) Polymorph selectivity under microscopic confinement. J Amer Chem Soc 126: 3382-3383
20. Chyall LJ, Tower JM, Coates DA, Houston TL Childs SL (2002) Polymorph generation in capillary spaces: the preparation and structural analysis of a metastable polymorph of nambumetone. Cryst Growth Des 2:505-510
21. Poornachary SK, Paramatril JV, Chow PS, Tan RBH Heng JVY (2013) Nucleation of elusive crystal polymorphs at the solution-substrate interface. Cryst Growth Des 13:1180-1186
22. Capes JS, Cameron RE (2007) Contact line crystallization to obtain metastable polymorphs. Cryst Growth Des 7:108-112
23. Mahieux J, Sanselme M, Cocquerel G (2013) Access to single crystals of (+/-) form IV of Modafinil by crystallization in gels: Comparison between (+/-) forms I, III, IV and (-) form I. Cryst Growth Des 13:98-917
24. Trask AV, Haynes DA, Motherwell WDS, Jones W (2006) Screening for co-crystals via mechanochemistry. Chem Commun 51-53
25. Teshima Y, Maeki M, Yamashita K, Miyazaki M (2013) A method for generating a metastable crystal in a microdroplet. CrystEngComm 15, 9874-9877
26. Nicholson CE, Chen C, Mendis B, Cooper SJ (2011) Stable polymorphs crystallized directly under thermodynamic control in three-dimensional nanoconfinement: a generic methodology. Cryst Growth Des 11:363-366
27. Benvenuti M, Mangani S (2007) Crystallization of soluble proteins in vapour diffusion for Xray crystallography. Nature Protocols 2:1633-1653
28. Lopez-Mejiers V, Kampf JW Matzger AJ (2012) Non-amorphism in flufenamic acid and a new record for a polymorphic compound with solved structures. J Amer Chem Soc 134:9872-9875
29. Krc J (1977) Crystallographic properties of flufenamic acid Microscope 25:31-54
30. Kuhnert-Brandstaetter M, Borka L, Friedrich-Sender G (1974) Polymorphism of drugs. Flufenamic acid and BL191. Archiv Pharm 307:854-853
31. Kuhnert-Brandstaetter M Aepers M (1962) Molecular compounds, crystalline solid solutions and new cases of polymorphism in barbiturates II. Mikrochim Acta 50:1055-1074: (1963): idem III. Mikrochim Acta 2:360-363
32. Zencirci N, Gelbrich T, Apperley DC, Harris RK, Kahlenberg V Griesser U (2012) Structural features, phase relationships and transformation behaviour of the polymorphs I-VI of phenobarbitone. Cryst Growth Des 10:302-313
33. Barsky NJ, Bernstein J, Stephens PW, Stone KH, Cheung E, Hickey MB (2008) Disappearing and reappearing polymorphism in p-methylchalcone. Cryst Growth Des 8:63-70
34. Weygand C (1929) Systematic investigation of the polymorphism of organic substances. Liebigs Ann 472:143-179
35. Stephenson GA, Groleau EG, Kleeman RL, Xu W, Rigsbee DL (1998) Formation of isomorphous desolvates: Creating a molecular vacuum. J Pharm Sci 87:536-542 (Pubitemid 28225615)
36. Deffet L (1942) Repertoire des composés organiques polymorphes. Desoer Liege
37. Perrin M-A, Bauer M, Barrio M, Tament JL, Ceolin R, Rietvelt IB (2013) Rimonabant dimorphism and the pressure-temperature phase diagram. A delicate case of overall monotropic behaviour. J Pharm Sci 102:2311-2321
38. Auer ME, Griesser UJ, Sawatski J (2003) Qualitative and quantitative study of polymorphic forms in drug formulations by near FT-Raman spectroscopy. J Mol Sci 661-662:307-317 (Pubitemid 38169065)
39. Mehrens SM, Kale UJ, Qu X, (2005) Statistical analysis of differences in the Raman spectra of polymorphs. J Pharm Sci 94:1354-1367 (Pubitemid 40904198)
40. Zeitler JA, Newnham DA, Taday PF, Threlfall TL, Lancaster RW, Berg RW, Strachan CJ, Pepper M, Gordon KC, Rades T (2006) Characterization of temperature-induced phase transformations in five polymorphs of sulfathiazole by terahertz pulsed spectroscopy and differential scanning calorimetry. J Pharm Sci 95:2485-2498
41. Boetker JP, Koradia V, Savolainen M, Rades T, Rantanen J (2012) Atomic pairwise distribution function analysis of the amorphous phase prepared by different routes. Pharmaceutics 4:93-103
42. Mynukh Y (2001) Fundamentals of phase transitions, ferroelectricity and ferromagnetism. First Books, New York
43. Threlfall TL (2003) Structural and thermodynamic explanations of Ostwald's rule. Org Process Res Dev 7:1017-1027
44. Newman AW, Reutzel-Edens SM, Zografi G (2008) Characterization of the "hygroscopic" properties of active pharmaceutical ingredients. J Pharm Sci 97:1047-1059
45. Naumov P, Jovanovski G, Gupee O, Kaitner B, Rae AD, Ng SW (2005) Solid state structures and temperature/evacuation-induced dehydration of sodium saccharinate 1.875 hydrate. Angew Chem Int Eng 44:1251
46. Harris, RK, Yeung RR, Lamont RB, Lancaster RW, Lynn SM, Staniforth SE (1997) 'Polymorphism' in a novel anti-viral agent: Lamuvidine. J Chem Soc Perkin 2 2653-2659 (Pubitemid 127438995)
47. Pesti JA, Huhn JF, Yin J, Xing Y, Fortunak JM, Earl RA (2000) Efficient pyridinyl functionalization: Synthesis of 10,10-bis[(2-fluoro-4-pyridinyl) methyl}9(10H)-anthacenone (DMP543) an acetylcholine release enhancing agent. J Org Chem 65:7718-7722
48. Ostwald W (1897) Studies of the formation and transformation of solid substances. Zeits Phys Chem 22:289-330
49. Borchert T (2001) The influence of impurity molecules on the crystallisation of polymorphs. Paper presented at the third international symposium on polymorphism and crystallisation San Francisco 12-13 November
50. Mc Crone WC (1965) Polymorphism. In physics and chemistry of the solid state Fox D, Labes MM, Weissberger A Wiley-Interscience New York Vol 2 725-767
51. Bernstein J (2005) ...And another comment on pseudopolymorphism. Cryst Growth Des 5:1661-1662
52. Seddon K (2004) Pseudopolymorph: a polemic. Cryst Growth Des 4:1087
53. Kosower EM (1962) Molecular Biochemistry. McGraw-Hill New York
54. Desiraju GR (2004) Crystal and co-crystal. Cryst Growth Des 4:1089-1096
55. Bingham A, Hughes D, Hursthouse MB, Lancaster RW, Tavener S, Threlfall TL (2001) Over 100 solvates of sulfathiazole. Chem Commun 603-604
56. Apperley DC, Fletton, RA, Harris RK, Lancaster RW, Tavener S, Threlfall TL (1999) Sulfathiazole polymorphism studied by magic angle spinning NMR. J Pharm Sci 88:1275-1280
57. Blagden N, Davey RJ, Roberts R, Rowe R (1998) Disappearing polymorphs and the role of reaction byproducts: the case of sulfathiazole. Int J Pharm 172:169-177 (Pubitemid 28430254)
58. Kaufmann GB, Belloni L (1987) Giorgio Piccardi (1895-1972) Italian physical chemist and master of the sun. J Chem Ed 64:205-8:
59. Piccardi G (1960) Surrounding space and life. Effect of terrestrial solar and cosmic phenomena on physico-chemical and biological processes. Minerva Medica 51:1554-1555
60. Nichols G, Frampton CS (1998) Physicochemical characterization of the orthorhombic polymorph of paracetamol crystallised from solution. J Pharm Sci 87:684-693
61. Dunn PJ, Hughes ML, Searle PM, Wood AE (2003) The chemical development and scale up of sampatrilat. Org Process Res Dev 7:244-257